ASC22 with peginterferon to cure chronic hepatitis B
Treatments studied
Part of Digestive system, Infections clinical trials.
This trial tests whether combining ASC22 with peginterferon can help people with chronic hepatitis B achieve a functional cure (clearing the virus for good). It's for patients whose HBsAg levels are very low and who are already on stable treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 70 years old
- You have chronic hepatitis B and are HBeAg-negative (a blood test result)
- Your HBsAg (hepatitis B surface antigen) level is less than 100 IU/mL
- Your HBV DNA (virus level) is undetectable or very low (under 20 IU/mL)
- You are not pregnant or breastfeeding, and you agree to use birth control during the study
- You do not have advanced liver damage (cirrhosis with complications, liver cancer, or significant fibrosis)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 study tests a combination treatment to help people with chronic hepatitis B stop having detectable hepatitis B surface antigen (called HBsAg). If successful, it may move you closer to a “functional cure,” meaning lower ongoing virus activity over time.
This Phase 2 study tests a combination therapy to help people with chronic hepatitis B reach a “functional cure,” meaning the hepatitis B surface antigen (HBsAg) is lost for a sustained period. If you qualify, you’ll be closely monitored to see how well the treatment works and whether it’s safe for you.
This study tests whether additional peginterferon treatment can further reduce the virus in the liver for people with chronic hepatitis B who have already reached a clinical cure. You would need to have two liver biopsies to check the virus levels.
This trial tests a new medicine (VIR-2218) combined with a standard injection (peginterferon) to see if it can better control chronic hepatitis B. It may be an option if your virus levels are low and you haven't had recent treatment.
This study looks at genetic factors that may help people with chronic hepatitis B achieve a clinical cure when treated with long-acting interferon. It aims to find out why some patients respond better than others.
This trial tests a combination of a PD-1 antibody (a type of immunotherapy) and peginterferon alpha for people with chronic hepatitis B whose virus is already under control but whose surface antigen levels haven't improved much with standard therapy. It aims to see if the combo can help reduce the hepatitis B surface antigen further.
Hear when a new Chronic Hepatitis B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.